Physician profile

Allen T Raphael

Podiatrist · Smyrna, GA

NPI 1770539801

$324,359.68

in general payments reported to CMS, 2019-2025

37 companies · $66K in 2025

The $66K reported for 2025 was more than what 99% of Podiatrist providers received nationally (typical 2025 total: $260).

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program$78,112.50
Consulting Fee$22,696.25
Travel and Lodging$20,042.30
Food and Beverage$7,070.39
Honoraria$5,200.00
Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program$2,000.00
Education$316.91

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Smith+Nephew, INC. $186,220.06 2019-2025 Grafix, Stravix, Grafix Pl
Kerecis Limited $51,392.66 2019-2025 Kerecis Surgiclose, Kerecis Graftguide, Kerecis Omega3 Marigen
Biotissue Holdings INC. $50,770.04 2019-2020
Amniox Medical, INC. $22,762.64 2019-2020
Melinta Therapeutics, LLC $11,180.43 2019-2025 Kimyrsa, Orbactiv
Stryker Corporation $429.84 2021-2023 N/A, Actishield, Augment Injectable
Osiris Therapeutics INC. $230.55 2019
Integra Lifesciences Corporation $144.78 2019-2025 Integra, Primatrix, Integra Dermal Regeneration Template
Davol INC. $141.01 2024 Arista Ah Flexitip
Wright Medical Technology, INC. $131.22 2019
Paratek Pharmaceuticals, INC. $107.21 2021-2024 Nuzyra
Becton, Dickinson and Company $106.84 2024 Arista Ah Flexitip
Medtronic, INC. $102.57 2025 Intellis Adaptivestim
Solventum Corporation $57.68 2024-2025 Activ.A.C., V.A.C. Veraflo
Amgen INC. $49.39 2024 Krystexxa
Show all 37 companies
CompanyGeneral paymentsYearsTop products
Zyla Life Sciences, INC. $45.49 2019
Polynovo North America LLC $43.81 2023-2024 Novosorb Btm
Hydrofera LLC $43.48 2022-2024 Hydrofera Blue
Tactile Systems Technology INC $39.76 2021
Bioventus LLC $34.87 2019
Aroa Biosurgery Incorporated $34.57 2020
Acell, INC. $27.03 2019
Geistlich Pharma, North America, INC. $26.69 2021
Averitas Pharma INC. $24.44 2023 Qutenza
Convatec INC. $22.54 2024
Ets Wound Care LLC $21.69 2025 Mirragen Advanced Wound Matrix
Treace Medical Concepts, INC. $20.57 2025
Inari Medical, INC. $19.65 2024 Flowtriever Catheter, S, Ct Thrombectomy System Kit
Paragon 28, INC. $17.91 2024 Apex 3d
Kci USA, INC. $16.66 2021
Ortho Dermatologics, A Division of Bausch Health US, LLC $15.85 2019
Acera Surgical, INC. $15.12 2022
Organogenesis INC. $14.95 2019
Merck Sharp & Dohme LLC $14.67 2019
Celularity INC. $13.00 2019
Omeza LLC $10.07 2024
Orthofix Medical, INC. $9.94 2020

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Allen T Raphael

$324,359.68

in general payments reported 2019-2025

Years
2019-2025
Top company
Smith+Nephew, INC.
Context
The $66K reported for 2025 was more than what 99% of Podiatrist providers received nationally (typical 2025 total: $260).

https://glasscript.com/doctor/34528/allen-t-raphael

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.